Email this article The combination therapy: when efficiency and safety go an arm about arm
- Authors: Chazova IE1, Ratova LG1
-
Affiliations:
- Issue: Vol 6, No 3 (2009)
- Pages: 25-27
- Section: Articles
- URL: https://journals.eco-vector.com/2075-082X/article/view/33064
- DOI: https://doi.org/10.26442/SG33064
- ID: 33064
Cite item
Full Text
Abstract
Aim: To evaluate efficacy and tolerance of a compound drug Co-renitec combining an ACE inhibitor enalapril maleate and diuretic
hydrochlorothiazide. Co-renitec taken for 16 weeks in patients with essential hypertension (EH). Material and methods: 28 patients
with EH (16 males and 12 females aged 47-74 years) of mean duration 132 years. Blood pressure (BP) was monitored for 24 hours
with the device SL 90207 (SpaceLabs Medical, USA). Microalbuminuria (MAU) was estimated with the use of immunoturbodimetric
test. Results: By 24-hour monitoring, Co-renitec reduced day BP by 15/9 - 3/2 mm Hg, nocturnal BP lowered by 19/12 - 3/2 mmHg,
pulse pressure also fell. Coefficient T/P was 53% for systolic BP (SBP) and 60% for diastolic BP (DBP). The target BP was reached in
70% patients. Co-renitec significantly decreased MAU, albumines excretion normalized in 46% patients. Conclusion: Co-renitec lowers
both day and nocturnal blood pressure, improves 24-h rhythm of BP, has a positive effect on the kidneys. This allows its recommendation
as a first-line drug in patients with moderate and severe EH.
hydrochlorothiazide. Co-renitec taken for 16 weeks in patients with essential hypertension (EH). Material and methods: 28 patients
with EH (16 males and 12 females aged 47-74 years) of mean duration 132 years. Blood pressure (BP) was monitored for 24 hours
with the device SL 90207 (SpaceLabs Medical, USA). Microalbuminuria (MAU) was estimated with the use of immunoturbodimetric
test. Results: By 24-hour monitoring, Co-renitec reduced day BP by 15/9 - 3/2 mm Hg, nocturnal BP lowered by 19/12 - 3/2 mmHg,
pulse pressure also fell. Coefficient T/P was 53% for systolic BP (SBP) and 60% for diastolic BP (DBP). The target BP was reached in
70% patients. Co-renitec significantly decreased MAU, albumines excretion normalized in 46% patients. Conclusion: Co-renitec lowers
both day and nocturnal blood pressure, improves 24-h rhythm of BP, has a positive effect on the kidneys. This allows its recommendation
as a first-line drug in patients with moderate and severe EH.
References
- Диагностика и лечение артериальной гипертензии. Российские рекомендации. Кардиоваск. тер. и проф. Прил. 2, 2008; 7 (6).
- ESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105-87.
- Whitworth JA. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21 (11): 1983-92.
- The HOT Study Group. The Hypertension Optimal Treatment Study (the HOT Study). Blood Pressure 1993; 2: 62-8.
- Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертонии: в фокусе - ингибиторы ангиотензинпревращающего фермента и диуретики. Consilium Medicum. 2007; 9 (5).
- Ратова Л.Г., Дмитриев В.В., Толпыгина С.Н., Чазова И.Е. Суточное мониторирование артериального давления в клинической практике. Артериальная гипертензия. 2001; 3-14.
Supplementary files
